Perspective Therapeutics Presents Interim Clinical Trial Results at ASCO

Perspective Therapeutics presented interim clinical findings from its [²¹²Pb]VMT-α-NET program at the 2026 American Society of Clinical Oncology Annual Meeting. The study is a multi-center, open-label dose-escalation trial examining the use of [²¹²Pb]VMT-α-NET in patients with unresectable or metastatic SSTR2-positive tumors. Efficacy results were presented for half of the patients in Cohort 2 and both patients in Cohort 1, while results for other cohorts are still pending.

The presentation of interim efficacy results for a radiopharmaceutical targeting somatostatin receptor subtype 2 is significant for the development of new cancer treatments. These findings could influence future investment and market perception of the company's pipeline.